# Century Therapeutics Inc. (IPSC) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $2.11, market value $382 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Century Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 3.5×**. Each dollar of revenue is priced at 3.5×.
- **Price / book: 1.6×**. The shares trade at 1.6× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -23.1%** (5-yr avg -73.6%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -15.8%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -8.8%**. The company reported a net loss over the last twelve months.
- **Return on equity: -6.0%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -13.5%**. Return on all capital, debt included, is -13.5%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -4.3%**. Each dollar of assets produces -4.3% of profit.

## Growth
- **Revenue growth (1 yr): 1556.8%** (3-yr 175.9%/yr). Revenue grew 1556.8% over the last year.
- **EPS growth (1 yr): 91.3%**. Earnings per share rose 91.3%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.02**. Debt is 0.02 times equity: a conservative balance sheet.
- **Current ratio: 5.97** (quick 5.97). Current assets cover the next year's liabilities 5.97 times.
- **Altman Z-score: 5.31**. A Z-score of 5.31 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Century Therapeutics Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 340.5%** (YTD 112.1%, 3-mo -0.9%). The shares are up 340.5% over twelve months including dividends.
- **From 52-week high: -30.6%** (385.1% above the low). Trading 31% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 52**. An RSI of 52 is neutral.
- **Beta (1 yr): 2.08** (volatility 97%). Beta of 2.08 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=IPSC · Page: https://foliofundamentals.com/stocks/ipsc

Not investment advice.